Cabozantinib inhibits multiple tyrosine kinases including MET, AXL, and VEGFR2 [6] that promote oncogenesis, angiogenesis, and resistance to antiangiogenic therapy in RCC. This evidence concerns the gene AXL and renal cell carcinoma.